DualityBio’s STAR Market IPO Application Officially Accepted by the Shanghai Stock Exchange

The Phase I/II Clinical Trial of the Novel EGFR/HER3 Bispecific ADC DB-1418/AVZO-1418 for Advanced Solid Tumors Completes First Patient Dosing in China,Aiming to Accelerate Clinical Development Jointly with Partner

First Patient Dosed in Global Pivotal Phase 3 Clinical Trial for BioNTech and DualityBio’s B7-H3 ADC DB-1311/BNT324 in Metastatic Castration-Resistant Prostate Cancer

2026 ESMO Breast Cancer | Presentation of Preliminary Clinical Data for DualityBio and BioNTech’s Next-Generation TROP2 ADC Sacituzumab Drozuntecan in First-Line Advanced TNBC

DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer

DualityBio’s DB-1310 Granted U.S. FDA Fast Track Designation for HR+/HER2- Breast Cancer